期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Kelp Fucoidans Facilitate Vascular Recanalization via Inhibiting Excessive Activation of Platelet in Deep Venous Thrombosis Model of Mouse
1
作者 sun taohua LIU Jie +2 位作者 YAN Taishan CHEN Anjin ZHANG Fang 《Journal of Ocean University of China》 CAS CSCD 2024年第2期550-556,共7页
This study was carried out explore the mechanism underlying the inhibition of platelet activation by kelp fucoidans in deep venous thrombosis(DVT)mouse.In the control and sham mice,the walls of deep vein were regular ... This study was carried out explore the mechanism underlying the inhibition of platelet activation by kelp fucoidans in deep venous thrombosis(DVT)mouse.In the control and sham mice,the walls of deep vein were regular and smooth with intact intima,myometrium and adventitia.The blood vessel was wrapped with the tissue and there was no thrombosis in the lumen.In the DVT model,the wall was uneven with thicken intima,myometrium and adventitia.After treated with fucoidans LF1 and LF2,the thrombus was dissolved and the blood vessel was recanalized.Compared with the control group,the ROS content,ET-1 and VWF content and the expression of PKC-βand NF-κB in the model were significantly higher(P<0.05);these levels were significantly reduced following treatments with LF2 and LF1.Compared with H_(2)O_(2)treated-HUVECs,combined LF1 and LF2 treatment resulted in significant decrease in the expression of PKC-β,NF-κB,VWF and TM protein(P<0.05).It is clear that LF1 and LF2 reduces DVT-induced ET-1,VWF and TM expressions and production of ROS,thus inhibiting the activation of PKC-β/NF-κB signal pathway and the activation of coagulation system and ultimately reducing the formation of venous thrombus. 展开更多
关键词 kelp fucoidans LF1 LF2 deep vein thrombosis PLATELET
下载PDF
酒精性肝病治疗研究进展 被引量:31
2
作者 孙韬华 刘振胜 辛永宁 《实用肝脏病杂志》 CAS 2019年第2期156-159,共4页
酒精性肝病(alcoholic liver disease,ALD)是长期大量饮酒导致的肝脏疾病,包括脂肪肝、酒精性肝炎(alcoholic hepatitis,AH)、肝纤维化和肝硬化等。严重酗酒时可诱发广泛肝细胞坏死,甚至引起肝功能衰竭。2018年,美国胃肠病学院(ACG)发... 酒精性肝病(alcoholic liver disease,ALD)是长期大量饮酒导致的肝脏疾病,包括脂肪肝、酒精性肝炎(alcoholic hepatitis,AH)、肝纤维化和肝硬化等。严重酗酒时可诱发广泛肝细胞坏死,甚至引起肝功能衰竭。2018年,美国胃肠病学院(ACG)发布酒精性肝病诊治临床指南,中华医学会肝病学会脂肪肝和酒精性肝病学组亦对酒精性肝病防治指南进行了更新。本文将结合指南对酒精性肝病治疗方面最新研究进展进行介绍。 展开更多
关键词 酒精性肝病 治疗 研究进展
下载PDF
三七总皂苷和灯盏花素单用与联用时主要成分的药动学比较 被引量:3
3
作者 孙韬华 闫泰山 +1 位作者 黎维勇 陈安进 《医药导报》 CAS 北大核心 2021年第1期39-44,共6页
目的考察三七总皂苷(主要成分为三七皂苷R1、人参皂苷Rg1、人参皂苷Re、人参皂苷Rb1、人参皂苷Rd)和灯盏花素(主要成分为野黄芩苷)复方粉针制剂在健康比格犬体内的药动学,并与单独使用三七总皂苷粉针或灯盏花素粉针时的药动学参数进行... 目的考察三七总皂苷(主要成分为三七皂苷R1、人参皂苷Rg1、人参皂苷Re、人参皂苷Rb1、人参皂苷Rd)和灯盏花素(主要成分为野黄芩苷)复方粉针制剂在健康比格犬体内的药动学,并与单独使用三七总皂苷粉针或灯盏花素粉针时的药动学参数进行比较。方法建立检测给药后不同时间点的比格犬血样中三七总皂苷各组分及野黄芩苷浓度的液相色谱-串联质谱联用(LC-MS/MS)方法,计算各成分的药动学参数。结果单次给予复方粉针后,三七皂苷R1、人参皂苷Rg1、人参皂苷Re、人参皂苷Rb1、人参皂苷Rd及野黄芩苷的血浆消除半衰期(t1/2)分别为(1.08±0.30),(0.95±0.16),(1.40±0.39),(51.08±10.42),(64.84±17.70)及(2.00±0.88)h;峰浓度(Cmax)分别为(4641.00±758.84),(11325.00±1418.62),(1822.00±253.37),(39380.00±5644.03),(12964.00±2738.41)及(2669.00±841.79)ng·mL-1;血药浓度-时间曲线下面积(AUC0-∞)分别为(2832.31±308.38),(3454.00±473.08),(1210.80±161.06),(1360410.90±277244.88),(320529.65±101345.47),(450.68±90.50)ng·mL-1·h。与三七总皂苷粉针或灯盏花素粉针单次给药相比,复方粉针单次给药后,血药浓度-时间曲线相似;三七皂苷R1、人参皂苷Rg1、人参皂苷Re、人参皂苷Rd的Cmax显著升高(P<0.05);人参皂苷Rb1和野黄芩苷Cmax差异无统计学意义(P>0.05);t1/2、AUC0-∞差异无统计学意义(P>0.05)。结论三七总皂苷粉针和灯盏花素粉针联合用药可提高三七总皂苷部分组分的Cmax,对野黄芩苷的药动学没有明显影响。 展开更多
关键词 三七总皂苷粉针 灯盏花素粉针 三七总皂苷和灯盏花素复方粉针 药动学
下载PDF
Studies on Antiviral and Immuno-Regulation Activity of Low Molecular Weight Fucoidan from Laminaria japonica 被引量:9
4
作者 sun taohua ZHANG Xinhui +4 位作者 MIAO Ying ZHOU Yang SHI Jie YAN Meixing CHEN Anjin 《Journal of Ocean University of China》 SCIE CAS CSCD 2018年第3期705-711,共7页
The antiviral activity in vitro and in vivo and the effect of the immune system of two fucoidan fractions with low molecular weight and different sulfate content from Laminaria japonica(LMW fucoidans) were investigate... The antiviral activity in vitro and in vivo and the effect of the immune system of two fucoidan fractions with low molecular weight and different sulfate content from Laminaria japonica(LMW fucoidans) were investigated in order to examine the possible mechanism. In vitro, I-type influenza virus, adenovirus and Parainfluenza virus I were used to infect Hep-2, Hela and MDCK cells, respectively. And 50% tissue culture infective dose was calculated to detect the antiviral activity of two LMW fucoidans. The results indicated that compared with the control group, 2 kinds of LMW fucoidans had remarkable antiviral activity in vitro in middle and high doses, while at low doses, the antiviral activity of 2 kinds of LMW fucoidans was not statistically different from that in the blank control group. And there was no statistically difference between two LMW fucoidans in antiviral activity. In vivo, LMW fucoidans could prolong the survival time of virus-infected mice, and could improve the lung index of virus-infected mice significantly, which have statistical differences with the control group significantly(p < 0.01). However, the survival time of the two LMW fucoidans was not statistically significant(p > 0.05). In this study, it was shown that both of two LMW fucoidans(LF1, LF2) could increase the thymus index, spleen index, phagocytic index, phagocytosis coefficient and half hemolysin value in middle and high doses, which suggested that LMW fucoidans could play an antiviral role by improving the quality of immune organs, improving immune cell phagocytosis and humoral immunity. 展开更多
关键词 免疫系统 抗病毒 低分子 装饰用 重量 梨树 流行性感冒病毒 VIVO
下载PDF
首个白介素-17A和白介素-17F双重抑制剂bimekizumab的研究进展
5
作者 张芳 刘杰 +1 位作者 孙韬华 赵艳 《世界临床药物》 2022年第3期336-341,共6页
白介素-17(interleukin-17,IL-17)包括IL-17A、IL-17F等6种亚型,在多种免疫介导的疾病的发病机理中起重要作用。目前上市的IL-17A抑制剂对于银屑病(psoriasis),银屑病关节炎(psoriatic arthritis)和强直性脊柱炎(ankylosing spondylitis... 白介素-17(interleukin-17,IL-17)包括IL-17A、IL-17F等6种亚型,在多种免疫介导的疾病的发病机理中起重要作用。目前上市的IL-17A抑制剂对于银屑病(psoriasis),银屑病关节炎(psoriatic arthritis)和强直性脊柱炎(ankylosing spondylitis)均有良好疗效。bimekizumab(UCB4940)是由比利时优时比公司研发的一种新型人源化免疫球蛋白G1单克隆抗体,其能够与IL-17A和IL-17F上的特定位点选择性结合,同时对IL-17A和IL-17F效果产生抑制作用,从而产生比单独抑制IL-17A更为强大的抗炎效果。最新Ⅲ期临床研究数据显示bimekizumab治疗银屑病的效果确切,且耐受性好。该文对bimekizumab的药理学、药代动力学、临床疗效评价及安全性等情况作一概述。 展开更多
关键词 白介素-17 抑制剂 银屑病 强直性脊柱炎 bimekizumab
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部